Estradiol Pellets Recalled Due to Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Estradiol 15 mg sterile pellets nationwide because FDA inspections identified GMP violations affecting sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. The hazard involves a sterile medical product with GMP violations impacting sterility, which poses a significant risk of serious injury (infection) if used, fitting the 'Severe' criteria for significant injury risk or Class II with potential for serious harm.
Plain-English summary
The Compounding Pharmacy of America is recalling Estradiol 15 mg, Sterile Pellets, manufactured in Knoxville, Tennessee. The recall covers 120-pellet packages distributed nationwide between November 2014 and May 2015. Specific lot codes and expiration dates are listed in the official recall notice.
The recall was initiated due to a lack of assurance of sterility. An FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility. No specific illnesses or injuries are reported in the source text.
Consumers who have purchased these products should stop using them and contact their healthcare provider or the recalling firm for instructions on return or replacement.
The recalled product
- Product
- Estradiol 15 mg, Sterile Pellet, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Hazard
- Affected units
- 120
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- All lots distributed between November 2014 and May 2015
- 11262014@20
- 5/25/2015
- 01152015@27
- 7/14/2015
- 02232015@21
- 8/22/2015
- 02242015@23
- 8/23/2015
- 05052015@68
- 11/1/2015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Estradiol Pellets Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-04
- SevereEstradiol Valerate Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-06-15
- SeverePartell Specialty Pharmacy Recalls Estradiol Pellets Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- ModerateQualgen Recalls Estradiol Pellets Due to Quality Assurance Deviations
FDA (Drugs) · 2017-06-14
- SevereQualgen Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2018-11-14